Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 33% Improvement Relative Risk Martinez-Lopez et al. HCQ for COVID-19 LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? Retrospective 167 patients in Spain Lower mortality with HCQ (not stat. sig., p=0.2) Martinez-Lopez et al., Blood Cancer J., doi:10.1038/s41408-020-00372-5 Favors HCQ Favors control
Multiple Myeloma and SARS-CoV-2 Infection: Clinical Characteristics and Prognostic Factors of Inpatient Mortality
Martinez-Lopez et al., Blood Cancer Journal, doi:10.1038/s41408-020-00372-5
Martinez-Lopez et al., Multiple Myeloma and SARS-CoV-2 Infection: Clinical Characteristics and Prognostic Factors of Inpatient.., Blood Cancer Journal, doi:10.1038/s41408-020-00372-5
Jun 2020   Source   PDF  
  All Studies   Meta
Retrospective 167 multiple myeloma patients in Spain, showing no significant difference in mortality with HCQ treatment in unadjusted results without group details. This study is excluded in the after exclusion results of meta analysis: unadjusted results with no group details.
risk of death, 33.0% lower, RR 0.67, p = 0.20, treatment 47 of 148 (31.8%), control 9 of 19 (47.4%), NNT 6.4.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Martinez-Lopez et al., 30 Jun 2020, retrospective, Spain, peer-reviewed, median age 71.0, 25 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: Martínez-López et al. Blood Cancer Journal (2020)10:103 ARTICLE Blood Cancer Journal Open Access Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality 1234567890():,; 1234567890():,; 1234567890():,; 1234567890():,; Joaquín Martínez-López 1, María-Victoria Mateos 2, Cristina Encinas3, Anna Sureda4, José Ángel Hernández-Rivas5, Ana Lopez de la Guía6, Diego Conde7, Isabel Krsnik8, Elena Prieto9, Rosalía Riaza Grau10, Mercedes Gironella 11, María Jesús Blanchard12, Nerea Caminos13, Carlos Fernández de Larrea14, María Alicia Senin15, Fernando Escalante16, José Enrique de la Puerta 17, Eugenio Giménez18, Pilar Martínez-Barranco19, Juan José Mateos20, Luis Felipe Casado21, Joan Bladé14, Juan José Lahuerta 1, Javier de la Cruz22 and Jesús San-Miguel 23 Abstract There is limited information on the characteristics, prognostic factors, and outcomes of patients with multiple myeloma (MM) hospitalized with COVID-19. This retrospective case series investigated 167 patients reported from 73 hospitals within the Spanish Myeloma Collaborative Group network in March and April, 2020. Outcomes were compared with 167 randomly selected, contemporary, age-/sex-matched noncancer patients with COVID-19 admitted at six participating hospitals. Among MM and noncancer patients, median age was 71 years, and 57% of patients were male; 75 and 77% of patients, respectively, had at least one comorbidity. COVID-19 clinical severity was moderate–severe in 77 and 89% of patients and critical in 8 and 4%, respectively. Supplemental oxygen was required by 47 and 55% of MM and noncancer patients, respectively, and 21%/9% vs 8%/6% required noninvasive/invasive ventilation. Inpatient mortality was 34 and 23% in MM and noncancer patients, respectively. Among MM patients, inpatient mortality was 41% in males, 42% in patients aged >65 years, 49% in patients with active/progressive MM at hospitalization, and 59% in patients with comorbid renal disease at hospitalization, which were independent prognostic factors on adjusted multivariate analysis. This case series demonstrates the increased risk and identifies predictors of inpatient mortality among MM patients hospitalized with COVID-19.
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop